Edgewise Therapeutics to Present at Upcoming Investor Conferences in June 2022

BOULDER, Colo.--(BUSINESS WIRE)-- Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle disorders, announced today that members of its senior management team will participate in the following upcoming investor conferences:

Jefferies Healthcare Conference
Presentation: Friday, June 10, 2022, at 10 am ET

Goldman Sachs Annual Global Healthcare Conference
Fire Side Chat: Wednesday, June 15, 2022, at 4 pm PT (7 pm ET)

The presentations will be webcast live under the Edgewise events page and will be accessible for replay following the presentations. It is recommended that users connect to the webcasts several minutes prior to the start to ensure a timely connection.

About Edgewise Therapeutics

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare neuromuscular and cardiac disorders for which there is significant unmet medical need. Guided by its holistic drug discovery approach to targeting the muscle as an organ, Edgewise has combined its foundational expertise in muscle biology and small molecule engineering to build its proprietary, muscle-focused drug discovery platform. Edgewise’s platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue. To learn more, go to: www.edgewisetx.com or follow us on LinkedIn, Twitter and Facebook.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220531005057/en/

Contacts

Investors & Media
Michael Carruthers
Chief Financial Officer
ir@edgewisetx.com

Source: Edgewise Therapeutics

Powered by Business Wire

View this news release online at:
http://www.businesswire.com/news/home/20220531005057/en

Back to news